Company intelligence / Profile preview

Claritas NucMed Technologies

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Claritas NucMed Technologies spun off from Claritas HealthTech in 2024 to commercialize nuclear medicine imaging software globally. Its lead product iPETcertum is FDA- and ANVISA-cleared, dramatically accelerating segmentation and quantification in PET imaging, with demonstrable ability to reduce scan time and isotope dosage while preserving diagnostic accuracy

Therapeutic areas: CardiovascularOncologyNeurologyOther
Modalities: Device (software-based diagnostic aid)AI-assisted diagnostic tool
Industry: Medical Imaging

Partnerships

New Vida Medicamentos e Productos Ltda. (Brazilian distribution partner)

Beyond the preview

Go deeper on Claritas NucMed Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Claritas NucMed Technologies.

Explore the full profile